Chargement en cours...
A pilot study: (131)I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Duke University Press
2008
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2613820/ https://ncbi.nlm.nih.gov/pubmed/18287339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2007-053 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|